MNK1 (IC50 = 1-2 nM); MNK2 (IC50 = 1-2 nM); PD-L1

Tomivosertib (eFT508) 以剂量依赖性方式降低肿瘤细胞系中丝氨酸 209 处的 eIF4E 磷酸化 (IC50 = 2–16 nM)。 Tomivosertib 对大约 50 种血液癌症中的多种 DLBCL 细胞系表现出抗增殖活性。 TMD8、OCI-Ly3 和 HBL1 DLBCL 细胞系对 tomivosertib 的敏感性与促炎细胞因子（如 TNF、IL-6、IL-10 和 CXCL10）产生的剂量依赖性减少有关。对 Tomivosertib 作用模式的更彻底分析表明，TNF 合成减少与 TNFα mRNA 半衰期缩短 2 倍相关[1]。

Tomivosertib (eFT508) 在 TMD8 和 HBL-1 ABC-DLBCL 模型中表现出显着的抗肿瘤活性，这两种模型都含有激活的 MyD88 突变。此外，在人类淋巴瘤模型中，tomovosertib 与 R-CHOP 成分以及 PCI-32765 和 Venetoclax 等全新靶向药物有效相互作用[1]。

在许多实体瘤和血液恶性肿瘤的发病机制中，信使 RNA (mRNA) 翻译失调。 MNK1 和 MNK2 磷酸化真核起始因子 4E (eIF4E) 和其他重要效应蛋白（如 hnRNPA1 和 PSF），以整合来自各种免疫和致癌信号通路（如 RAS、p38 和 Toll 样受体 (TLR) 通路）的信号。 MNK1 和 MNK2 通过这些调节蛋白的磷酸化专门控制细胞 mRNA 的稳定性和翻译子集。 eFT508 是一种强效、选择性极高、可口服生物利用的 MNK1 和 MNK2 抑制剂。在酶测定中，eFT508 通过 ATP 竞争性可逆机制抑制激酶，对两种 MNK 同工型的半数抑制浓度 (IC50) 为 1-2 nM。

用eFT508治疗肿瘤细胞系导致eIF4E丝氨酸209位点磷酸化的剂量依赖性降低(IC50 = 2-16 nM)，这与先前的研究结果一致，即该位点的磷酸化仅依赖于MNK1/MNK2。在约50例血液肿瘤中，eFT508对多种DLBCL细胞系显示出抗增殖活性。TMD8、OCI-Ly3和HBL1 DLBCL细胞系对eFT508的敏感性与促炎细胞因子(包括TNFα、IL-6、IL-10和CXCL10)的产生呈剂量依赖性减少有关。进一步评估eFT508的作用机制表明，TNFα产生的减少与TNFα mRNA半衰期减少2倍相关。[1]

---

荧光素酶检测。[2]
KRASG12D和MYCTg;KRASG12D细胞在12孔板中转染200 ng pGL3 (Firelfy荧光素酶)构建物，其中含有PD-L1全长或突变的5'UTR和40 ng pRL (Renilla荧光素酶)质粒，使用Lipofectamine 2000根据制造商的说明。转染24 h后收集细胞，一半细胞用Dual luciferase kit检测，另一半细胞用TRIzol纯化RNA。将萤火虫的荧光素酶活性归一化为鼠兔的活性，并进一步归一化为萤火虫和鼠兔荧光素酶RNA的RT-qPCR定量。

---

将 eFT508 按建议浓度应用于 TMD8 细胞 24 小时。 m7-GTP 用于细胞裂解物。免疫印迹用于检查琼脂糖凝胶拉下的蛋白质和结合的蛋白质。

Intrahepatic metastatic HCC graft implantation and drug treatment.[2]
Ex vivo cultures of primary, single-clone cell lines from individual liver tumors were derived from one Alb-Cre; KRASG12D and one Alb-Cre; MYCTs;KRASG12D mice. HCC cells described above were trypsinized, counted and 5 ×105 of cells were injected into the subcapsular region of the median liver lobe of C57BL/6 mice. Analgesics including bupivacaine and buprenorphine were given to the mice, while meloxicam was not given as it may have an effect on the tumor immune microenvironment. Primary liver tumor formation was detected at day 4. Over 70% of the mice successfully develop lung metastasis at days 12–18. Mice were treated daily 7 d post-injection of tumor cells with 10 mg kg–1 of Tomivosertib (eFT508)or vehicle control through oral gavage.[2]

---

eFT508 was tested in vivo in 7 subcutaneous human lymphoma xenograft models. Significant anti-tumor activity was observed in the TMD8 and HBL-1 ABC-DLBCL models, both of which harbor activating MyD88 mutations.

Results for clinical and pharmacokinetic endpoints
Participant characteristics are summarized in Supplementary Tables S1 and S2. Nineteen patients with metastatic breast cancer ranging in age from 27 to 77 were enrolled. The study population included patients with estrogen receptor–positive (ER+), Her2-positive, and triple-negative types of breast cancer. To be eligible, participants had to have progressive disease on approved therapies or refused approved therapies. As shown in Supplementary Table S3, the majority were heavily pretreated for metastatic breast cancer.
Safety was evaluated during the 2-week run-in period in which tomivosertib was given as a single agent and during subsequent treatment in which tomivosertib was given in combination with paclitaxel. As shown in Supplementary Tables S4A, S4B, S5, and S6, no patient stopped treatment for adverse events related to tomivosertib toxicity. Physician-determined adverse reactions related to tomivosertib were mostly low-grade changes in serum biochemistry results, including liver enzymes.
Pharmacokinetic studies were undertaken in 12 patients, and results are shown in Supplementary Fig. S2A and S2B. As expected, serum paclitaxel was undetectable during the tomivosertib-alone run-in period and peaked at the end of infusion at ∼2,200 ng/mL followed by a rapid drop to ∼ 400 ng/mL 1 hour after the end of infusion and a steady decline over the subsequent 36 hours. When paclitaxel was administered, patients were already receiving oral tomivosertib, and the presence of tomivosertib was noted to have no major effect on paclitaxel levels previously observed following infusion as a single agent. This finding is consistent with the absence of observed increase in paclitaxel toxicity in the presence of tomivosertib. Tomivosertib serum levels following oral dosing at 100 mg orally twice daily exhibited some variability between patients, but the minimum concentration remained above 98 ng/mL in three patients who took the drug at 100 mg twice daily without meals, whereas the minimum concentration was above 156 ng/mL in nine patients who took the drug at this dose with meals. Importantly, there was no major change in tomivosertib concentration whether paclitaxel was present or not. The measured serum concentrations were in a range previously observed to have in vitro activity.
As a phase Ib study, the study was designed primarily to provide information about safety, pharmacokinetics, and pharmacodynamics. No conclusions can be drawn about clinical utility in view of the absence of a control group and the small number of patients. As shown in Fig. 2, one patient had stable disease for 13 months and two others had stable disease for 8 months while receiving treatment according to the protocol.
https://pubmed.ncbi.nlm.nih.gov/39576211/

[1]. eFT508, a Potent and Selective Mitogen-Activated Protein Kinase Interacting Kinase (MNK) 1 and 2 Inhibitor, Is Efficacious in Preclinical Models of Diffuse Large B-Cell Lymphoma (DLBCL). Blood 2015 126:1554.

[2]. Translation control of the immune checkpoint in cancer and its therapeutic targeting. Nat Med. 2019 Feb;25(2):301-311.

Tomivosertib is under investigation in clinical trial NCT03318562 (A PD Study of Oral eFT508 in Subjects With Advanced TNBC and HCC).
Tomivosertib is an orally bioavailable inhibitor of mitogen-activated protein kinase (MAPK)-interacting serine/threonine-protein kinase 1 (MNK1) and 2 (MNK2), with potential antineoplastic activity. Upon oral administration, tomivosertib binds to and inhibits the activity of MNK1 and 2. This prevents MNK1/2-mediated signaling, and inhibits the phosphorylation of certain regulatory proteins, including eukaryotic translation initiation factor 4E (eIF4E), that regulate the translation of messenger RNAs (mRNAs) involved in tumor cell proliferation, angiogenesis, survival and immune signaling. This inhibits tumor cell proliferation in MNK1/2-overexpressing tumor cells. MNK1/2 are overexpressed in a variety of tumor cell types and promote phosphorylation of eIF4E; eIF4E is overexpressed in many tumor cell types and contributes to tumor development, maintenance and resistance.

C17H20N6O2

340.38

340.164

C, 59.99; H, 5.92; N, 24.69; O, 9.40

1849590-01-7

1849590-02-8 (HCl);1849590-01-7;

118598754

Off-white to yellow solid powder

1.4±0.1 g/cm3

735.6±60.0 °C at 760 mmHg

398.7±32.9 °C

0.0±2.4 mmHg at 25°C

1.688

1.12

113

3

6

2

25

664

0

O=C1C2=C(C([H])([H])[H])C([H])=C(C(N2C2(C([H])([H])C([H])([H])C([H])([H])C([H])([H])C2([H])[H])N1[H])=O)N([H])C1C([H])=C(N([H])[H])N=C([H])N=1

HKTBYUWLRDZAJK-UHFFFAOYSA-N

InChI=1S/C17H20N6O2/c1-10-7-11(21-13-8-12(18)19-9-20-13)16(25)23-14(10)15(24)22-17(23)5-3-2-4-6-17/h7-9H,2-6H2,1H3,(H,22,24)(H3,18,19,20,21)

6-[(6-aminopyrimidin-4-yl)amino]-8-methylspiro[2H-imidazo[1,5-a]pyridine-3,1'-cyclohexane]-1,5-dione

2934.99.9001

Powder      -20°C    3 years

                     4°C     2 years

In solvent   -80°C    6 months

                  -20°C    1 month

Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)

配方 1 中的溶解度: ≥ 0.44 mg/mL (1.29 mM) (饱和度未知) in 10% DMSO + 90% Corn Oil (这些助溶剂从左到右依次添加，逐一添加), 澄清溶液。
例如，若需制备1 mL的工作液，可将100 μL 4.4 mg/mL 澄清 DMSO 储备液加入900 μL 玉米油中，混合均匀。

---

配方 2 中的溶解度: ≥ 0.43 mg/mL (1.26 mM) (饱和度未知) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (这些助溶剂从左到右依次添加，逐一添加), 澄清溶液。
例如，若需制备1 mL的工作液，可将 100 μL 4.3 mg/mL澄清DMSO储备液加入400 μL PEG300中，混匀；然后向上述溶液中加入50 μL Tween-80，混匀；加入450 μL生理盐水定容至1 mL。
*生理盐水的制备：将 0.9 g 氯化钠溶解在 100 mL ddH₂O中，得到澄清溶液。

---

View More

配方 3 中的溶解度: 0.4 mg/mL (1.18 mM) in 5% DMSO + 40% PEG300 + 5% Tween80 + 50% Saline (这些助溶剂从左到右依次添加，逐一添加), 悬浊液; 超声助溶。
*生理盐水的制备：将 0.9 g 氯化钠溶解在 100 mL ddH₂O中，得到澄清溶液。

---

配方 4 中的溶解度: 0.4 mg/mL (1.18 mM) in 5% DMSO + 95% (20% SBE-β-CD in Saline) (这些助溶剂从左到右依次添加，逐一添加),悬浊液; 超声助溶。

---

请根据您的实验动物和给药方式选择适当的溶解配方/方案：
1、请先配制澄清的储备液(如：用DMSO配置50 或 100 mg/mL母液(储备液));
2、取适量母液，按从左到右的顺序依次添加助溶剂，澄清后再加入下一助溶剂。以 下列配方为例说明 (注意此配方只用于说明，并不一定代表此产品 的实际溶解配方):
10% DMSO → 40% PEG300 → 5% Tween-80 → 45% ddH2O (或 saline);
假设最终工作液的体积为 1 mL, 浓度为5 mg/mL: 取 100 μL 50 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀/澄清；向上述体系中加入50 μL Tween-80，混合均匀/澄清；然后继续加入450 μL ddH2O (或 saline)定容至 1 mL；
3、溶剂前显示的百分比是指该溶剂在最终溶液/工作液中的体积所占比例;
4、 如产品在配制过程中出现沉淀/析出，可通过加热(≤50℃)或超声的方式助溶;
5、为保证最佳实验结果，工作液请现配现用！
6、如不确定怎么将母液配置成体内动物实验的工作液，请查看说明书或联系我们;
7、 以上所有助溶剂都可在 Invivochem.cn网站购买。